Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Occuring Within the First 66 Days of Dosing - Part 1

  Measured over: Post dose on Day 1 up to Day 66 in Part 1

• Number of Participants With All-Causality Clustered Treatment-Emergent Cytopenias by Preferred Term (PT) and Max CTCAE Grade Occuring Within the First 66 Days of Dosing - Part 1

  Measured over: Post dose on Day 1 up to Day 66 in Part 1

• Number of Participants With All-Causality TEAEs During the Overall Period of Part 1

  Measured over: Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)

• Number of Participants With Treatment-Related TEAEs During the Overall Period of Part 1

  Measured over: Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)

• Number of Participants With All-Causality Clustered Treatment-Emergent Cytopenias by PT and Max CTCAE Grade Occuring Anytime After Dosing - Part 1

  Measured over: Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)

• Number of Participants With Treatment-Related Clustered Treatment-Emergent Cytopenias by PT and Max CTCAE Grade in >=10% of Participants Occuring Anytime After Dosing - Part 1

  Measured over: Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)

• Blinded Independent Central Review (BICR) Assessed Radiographic Progression-Free Survival (rPFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for All-Comers - Part 2 Cohort 1

  Measured over: From the start of treatment to the time of first documented progression, or death (maximum up to 42 months)

• BICR Assessed rPFS Per RECIST 1.1 in Patients With DDR Deficiencies - Part 2

  Measured over: From the start of treatment to the time of first documented progression, or death (maximum up to 38 months)

Changes Tremor has spotted